EUVIMEDEUVIMED entdecken
Crossref

sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension

Chao Liu, Bao-Chen Qiu, Shuang-Ping Li, Jing-Si Ma, Meng-Yi Liu, Si-Jin Zhang, Xi-Jie Zhu, Yin-Jian Yang, Tian-Yu Lian, Ying-Ying Cheng, Hui-Hui Xu, Yu-Ping Zhou und 9 weitere

European Respiratory Journal · 2026-06 · 67 (6) · 2502367

DOI: 10.1183/13993003.02367-2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 22.01.2026. Verfasst von Chao Liu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Scien…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Interleukin-6, Interleukin-1 Receptor-Like 1 Protein, Pulmonary Embolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangdong Provincial Science and Technology Planning Project, National High-Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate risk stratification is crucial for guiding therapy in medically treated chronic thromboembolic pulmonary hypertension (CTEPH), in which inflammation plays a key pathogenic role. This study aimed to identify and validate prognostic inflammatory biomarkers in medically treated CTEPH, with the goal of refining risk assessment and improving clinical management.

Methods

This dual-cohort study enrolled 576 medically treated CTEPH patients (discovery cohort: n=372; validation cohort: n=204) from 2009 to 2021. Plasma levels of inflammatory biomarkers, including soluble suppression tumorigenicity-2 (sST2), galectin-3 and a panel of cytokines, were measured in all participants. The study end-point was all-cause mortality. The prognostic significance of inflammatory markers was evaluated using Kaplan–Meier survival analysis, Cox regression models, C-index, net reclassification improvement and integrated discrimination improvement.

Results

Plasma sST2 and interleukin-6 (IL-6) were identified as predictors of survival, and remained robust predictors of mortality after comprehensive adjustment for clinical covariates in both cohorts. Risk stratification using the sST2/IL-6 panel revealed distinct 5-year survival rate gradients: high sST2/high IL-6 (34.4%), low sST2/high IL-6 (61.4%), high sST2/low IL-6 (78.3%) and low sST2/low IL-6 (90.5%) in the discovery cohort (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryInterleukin-6Interleukin-1 Receptor-Like 1 ProteinPulmonary EmbolismHumansFemaleMalePrognosisMiddle AgedBiomarkersAgedChronic DiseaseRisk AssessmentKaplan-Meier EstimateCohort StudiesProportional Hazards Models

Substanzen

Interleukin-6Interleukin-1 Receptor-Like 1 ProteinIL1RL1 protein, humanBiomarkersIL6 protein, human

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
  • These authors contributed equally to this work as co-first authors.
  • Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • College of Clinical Medicine, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, China.
  • Institute of Clinical Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of School of Pharmacy, Henan University, Kaifeng, China.

ORCID-Profile: Zhi-Cheng Jing

Förderung

  • National Key Research and Development Program of China
  • Guangdong Provincial Science and Technology Planning Project
  • National High-Level Hospital Clinical Research Funding
  • Postdoctoral Fellowship Program Grade B
  • Funding Non- communicable Chronic Diseases- National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Shenzhen Medical Research Fund
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Liu, C., Qiu, B. C., Li, S. P., Ma, J. S., Liu, M. Y., Zhang, S. J., Zhu, X. J., Yang, Y. J., Lian, T. Y., Cheng, Y. Y., Xu, H. H., Zhou, Y. P., Li, J. H., Wu, W. H., Xu, X. Q., Mao, Y. M., Cheng, C. Y., Jiang, X., Sun, K., …, & Jing, Z. C. (2026). sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 67(6), 2502367. https://doi.org/10.1183/13993003.02367-2025

Vancouver

Liu C, Qiu BC, Li SP, Ma JS, Liu MY, Zhang SJ, et al. sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension. European Respiratory Journal. 2026;67(6):2502367. doi:10.1183/13993003.02367-2025

BibTeX
@article{Liu2026,
  author = {Liu, Chao and Qiu, Bao-Chen and Li, Shuang-Ping and Ma, Jing-Si and Liu, Meng-Yi and Zhang, Si-Jin and Zhu, Xi-Jie and Yang, Yin-Jian and Lian, Tian-Yu and Cheng, Ying-Ying and Xu, Hui-Hui and Zhou, Yu-Ping and Li, Jing-Hui and Wu, Wen-Hui and Xu, Xi-Qi and Mao, Yi-Min and Cheng, Chun-Yan and Jiang, Xin and Sun, Kai and Zhang, Ze-Jian and Jing, Zhi-Cheng},
  title = {sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {6},
  pages = {2502367},
  doi = {10.1183/13993003.02367-2025}
}
Kostenlos starten →